Clinical Trial Update: Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab

View source ↗

Summary

A post-authorization safety study is evaluating safety outcomes of allogeneic hematopoietic stem cell transplantation in patients previously treated with mogamu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• T-cell Leukemia Lymphoma

Drugs mentioned

• Mogamulizumab (mogamulizumab)

Snippet

Sponsor: Kyowa Kirin, Inc. | Conditions: Leukemia/Lymphoma, Cutaneous T Cell Lymphoma | Status: RECRUITING